Global Market Research Group

"Global Atrial Fibrillation Market (Non-Surgical/Catheter, Surgical- Mini Maze, Hybrid): Analysis By Region, By Country (2016-2021) (By Procedures: Surgical Ablation- Mini Maze, Hybrid, Non-Surgical - Catheter:By Region-North America, Europe, APAC, ROW:By Country: U.S., Canada, UK, Germany, China, Japan)" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. . . Description- ' ' -- Executive Summary A comprehensive research report titled Global Atrial Fibrillation (Afib) Market (Non-Surgical/Catheter, Surgical- Mini Maze, Hybrid): Analysis By Region, By Country (2016-2021F) created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, presents the analysis of the global atrial fibrillation or Afib market and has been segmented By Procedures (Surgical Ablation- Mini Maze, Hybrid,

"Atrial Fibrillation Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2026" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. . . Description- ' ' -- -- Global Atrial Fibrillation Market: Overview -- -- Atrial fibrillation is an irregular heartbeat identified by the rapid and abnormal beating of the heart. The global market for atrial fibrillation is majorly driven by the rise in high blood pressure and valvular heart disease. Meanwhile, increasing prevalence of atrial fibrillation among the geriatric population is also fueling the growth of the market. Significant technological advancement is leading to the development of new monitoring technologies that can help patients as well as clinicians to keep a close watch and treat it on time. Smart, wireless, easy-to-use, cost-effective, and efficient

"Global Atrial Fibrillation Market Professional Survey Report 2016" The Report covers current Market Trends, Analysis, Forecast, Review, Share, Size, Growth, Effect. Description- Notes: Production, means the output of Atrial Fibrillation Revenue, means the sales value of Atrial Fibrillation This report studies Atrial Fibrillation in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, with production, revenue, consumption, import and export in these regions, from 2011 to 2015, and forecast to 2021. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering Boehringer Ingelheim Janssen Pharmaceuticals Sanofi ARCA Biopharma Get Sample Report With TOC @ http://www.researchmoz.us/enquiry.php?type=S&repid=859804 Armetheon Baxter Bristol-Myers Squibb ChanRx Daiichi Sankyo Gilead Sciences HUYA Bioscie

"Atrial Fibrillation Global Clinical Trials Review, H2, 2016" The Report covers current Market Trends, Analysis, Forecast, Review, Share, Size, Growth, Effect. Description- GlobalData's clinical trial report, Atrial Fibrillation Global Clinical Trials Review, H2, 2016" provides an overview of Atrial Fibrillation clinical trials scenario. This report provides top line data relating to the clinical trials on Atrial Fibrillation. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different

"PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025" The Report covers current Market Trends, Analysis, Forecast, Review, Share, Size, Growth, Effect. Description- Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregular and often abnormally fast heart rate. Various therapeutic options are available to treat patients with AF, and most patients will receive some form of antithrombotic therapy, a heart rate control agent, and potentially an antiarrhythmic drug for rhythm control. Get Sample Report With TOC @ http://www.researchmoz.us/enquiry.php?type=S&repid=855952 All sectors of the AF market have historically been saturated with generics, with the vitamin K antagonists such as warfarin playing an important role in stroke prevention in AF. However, since 2010, and the launch of the first of the new oral anticoagulants (NOACs), a shift in the treat